-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★ NK cells combined with CD38 antibody for the treatment of multiple myeloma Yimai Meng broke the news ★ WuXi Giant Nuo targeted BCMA CAR-T for clinical application Yimai Meng broke the news.
Click on the picture and register now July 9, 2021 Japan/MedClub News/--Recently, Eureka Therapeutics and Memorial Sloan Kettering Cancer Center (MSKCC) and Sanofi reached a license agreement on the "non-CAR use of human GPRC5D binding domain", aiming to develop potential Multiple myeloma therapy
.
The GPRC5D binding domain was discovered based on Eureka's proprietary E-ALPHA® antibody discovery platform, and was developed by Eureka and MSKCC in cooperation
.
According to the terms of the agreement, Sanofi has the exclusive right to use the GPRC5D binding domain for non-CAR
.
Eureka and MSKCC are eligible for upfront payments and potential development, regulatory and sales milestone payments of more than $1 billion; they are also eligible for gradient license fees for net sales
.
Dr.
Eric L.
Smith, a myeloma physician and patent inventor, said: “GPRC5D is a new target that is promising for the treatment of multiple myeloma, especially for patients who have relapsed after receiving other treatments
.
” Eureka CEO and President Dr.
Cheng Liu said: "We are pleased to provide technology for the development of next-generation therapies for multiple myeloma.
Targeting GPRC5D may increase the durability of current therapies and improve the long-term clinical benefits of patients
.
" Sanofi is no stranger to the field of myeloma
.
In March 2020, the FDA approved the company's monoclonal antibody Sarclisa (isatuximab) combined with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma
.
Just in March of this year, the FDA approved Sarclisa for another group of combination therapies (carfilzomib and dexamethasone) for this indication
.
Now Sanofi is focusing on the future of treating this disease and further strengthens its strength in this field; at the same time, this transaction is also a big gain for Eureka
.
Eureka Therapeutics is a clinical-stage biopharmaceutical company for novel T cell therapies, and it has now reached the E round of financing
.
Utilizing two core technology platforms, the Antibody-TCR ARTEMIS® platform and the E-ALPHA® antibody screening platform independently developed by Eureka, Eureka has developed a wealth of innovative T cell immunotherapy research and development pipelines that are safer and more effective for a variety of solid tumors and hematological tumors.
.
Recommended reading: Official announcement: Eureka completed US$45 million in Series E financing, and reached a strategic partnership with Lyell Immunopharma GPRC5D as a new target for multiple myeloma.
On March 27, 2019, researchers from Eureka Therapeutics, MSKCC and Juno Therapeutics were in Science A proof-of-concept research result entitled "GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR-T cells" was published in the journal Translational Medicine
.
For more details, scan the QR code for a complete reading.
▲ The development of GPRC5D targeting CAR (picture source: Science Translational Medicine) These research results show that GPRC5D has excellent potential in the treatment of multiple myeloma
.
Multiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin's lymphoma
.
In this disease, clonal plasma cells in the bone marrow deteriorate and abnormally proliferate.
Malignant plasma cells can replace normal blood cells in the body, leading to anemia and uncontrollable bleeding
.
It can also cause bone density and strength problems, and increase the risk of infection by reducing the body's immune response
.
In recent years, although great progress has been made in chemotherapy, proteasome inhibitors, and immunomodulator thalidomide derivatives, almost all patients will eventually relapse
.
Therefore, there is an urgent need for new treatment options
.
With the in-depth study of the disease biology and therapeutic targets of multiple myeloma, some targeted therapies have shown good therapeutic effects
.
Today, the CD38 antibody has been among the first-line treatments and sales are rising rapidly
.
The BCMA target has also been successful, BCMA ADC drugs and BCMA CAR-T have been approved for marketing, and Legendary Bio's BCMA CAR-T has submitted a marketing application
.
Preliminary clinical data have also been obtained for GPRC5D and FcRH5
.
Recommended reading: Janssen CD38 monoclonal antibody was once again approved as a first-line therapy, and the development of various targeted therapies for multiple myeloma is positive.
Yimai Meng broke the news that the first ADC drug targeting BCMA was submitted for marketing, and multiple myeloma benefited from The comprehensive development of CAR-T and bispecific antibodies based on this targetYi Mai Meng broke the news! The first BCMA CAR-T was approved for listing! Yimai Meng broke the news that the US FDA granted the legendary biological BCMA CAR-T priority review qualification, which is expected to be approved for listing this year.
Yimai Meng broke the news that GPRC5D is an emerging target, and there are not many relevant research and enterprise layouts at present: MSKCC's GPRC5D CAR-T cell therapy MCARH109, in phase 1 clinical trial (NCT04555551); Eureka's BCMA/GPRC5D dual-targeted CAR-T therapy; and Johnson & Johnson developed GPRC5D/CD3 dual antibody Talquetamab, the total response rate of the phase 1 study (ORR) up to 70%
.
GPRC5D (an orphan G protein-coupled receptor) exposed epitopes on the cell membrane transmits extracellular signals, which can promote the formation of tighter immune synapses between T cells and target cells, thereby increasing cytotoxicity
.
GPRC5D is a seven-pass transmembrane protein with a very complex structure, which brings great challenges to antibody preparation and activity analysis
.
Reference materials: 1.
https:// / /485/eaau7746/tab-figures-data4.
Kaifa Bio "Global First Release of GPRC5D Full-length Protein" 5.
Medical Notes "Multiple Myeloma Enters the Era of Macromolecules: CD38-BCMA-GPRC5D" Yimaike is always committed With original news reports on cutting-edge technologies, industry trends, and industry insights in bio-innovative drugs, the number of high-end matrix users in all media reached 160,000+, of which industrial users accounted for more than 50%, scientific research and clinical users accounted for about 30%, and investment institutional users exceeded 5%
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
Click on the picture and register now July 9, 2021 Japan/MedClub News/--Recently, Eureka Therapeutics and Memorial Sloan Kettering Cancer Center (MSKCC) and Sanofi reached a license agreement on the "non-CAR use of human GPRC5D binding domain", aiming to develop potential Multiple myeloma therapy
.
The GPRC5D binding domain was discovered based on Eureka's proprietary E-ALPHA® antibody discovery platform, and was developed by Eureka and MSKCC in cooperation
.
According to the terms of the agreement, Sanofi has the exclusive right to use the GPRC5D binding domain for non-CAR
.
Eureka and MSKCC are eligible for upfront payments and potential development, regulatory and sales milestone payments of more than $1 billion; they are also eligible for gradient license fees for net sales
.
Dr.
Eric L.
Smith, a myeloma physician and patent inventor, said: “GPRC5D is a new target that is promising for the treatment of multiple myeloma, especially for patients who have relapsed after receiving other treatments
.
” Eureka CEO and President Dr.
Cheng Liu said: "We are pleased to provide technology for the development of next-generation therapies for multiple myeloma.
Targeting GPRC5D may increase the durability of current therapies and improve the long-term clinical benefits of patients
.
" Sanofi is no stranger to the field of myeloma
.
In March 2020, the FDA approved the company's monoclonal antibody Sarclisa (isatuximab) combined with pomalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma
.
Just in March of this year, the FDA approved Sarclisa for another group of combination therapies (carfilzomib and dexamethasone) for this indication
.
Now Sanofi is focusing on the future of treating this disease and further strengthens its strength in this field; at the same time, this transaction is also a big gain for Eureka
.
Eureka Therapeutics is a clinical-stage biopharmaceutical company for novel T cell therapies, and it has now reached the E round of financing
.
Utilizing two core technology platforms, the Antibody-TCR ARTEMIS® platform and the E-ALPHA® antibody screening platform independently developed by Eureka, Eureka has developed a wealth of innovative T cell immunotherapy research and development pipelines that are safer and more effective for a variety of solid tumors and hematological tumors.
.
Recommended reading: Official announcement: Eureka completed US$45 million in Series E financing, and reached a strategic partnership with Lyell Immunopharma GPRC5D as a new target for multiple myeloma.
On March 27, 2019, researchers from Eureka Therapeutics, MSKCC and Juno Therapeutics were in Science A proof-of-concept research result entitled "GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR-T cells" was published in the journal Translational Medicine
.
For more details, scan the QR code for a complete reading.
▲ The development of GPRC5D targeting CAR (picture source: Science Translational Medicine) These research results show that GPRC5D has excellent potential in the treatment of multiple myeloma
.
Multiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin's lymphoma
.
In this disease, clonal plasma cells in the bone marrow deteriorate and abnormally proliferate.
Malignant plasma cells can replace normal blood cells in the body, leading to anemia and uncontrollable bleeding
.
It can also cause bone density and strength problems, and increase the risk of infection by reducing the body's immune response
.
In recent years, although great progress has been made in chemotherapy, proteasome inhibitors, and immunomodulator thalidomide derivatives, almost all patients will eventually relapse
.
Therefore, there is an urgent need for new treatment options
.
With the in-depth study of the disease biology and therapeutic targets of multiple myeloma, some targeted therapies have shown good therapeutic effects
.
Today, the CD38 antibody has been among the first-line treatments and sales are rising rapidly
.
The BCMA target has also been successful, BCMA ADC drugs and BCMA CAR-T have been approved for marketing, and Legendary Bio's BCMA CAR-T has submitted a marketing application
.
Preliminary clinical data have also been obtained for GPRC5D and FcRH5
.
Recommended reading: Janssen CD38 monoclonal antibody was once again approved as a first-line therapy, and the development of various targeted therapies for multiple myeloma is positive.
Yimai Meng broke the news that the first ADC drug targeting BCMA was submitted for marketing, and multiple myeloma benefited from The comprehensive development of CAR-T and bispecific antibodies based on this targetYi Mai Meng broke the news! The first BCMA CAR-T was approved for listing! Yimai Meng broke the news that the US FDA granted the legendary biological BCMA CAR-T priority review qualification, which is expected to be approved for listing this year.
Yimai Meng broke the news that GPRC5D is an emerging target, and there are not many relevant research and enterprise layouts at present: MSKCC's GPRC5D CAR-T cell therapy MCARH109, in phase 1 clinical trial (NCT04555551); Eureka's BCMA/GPRC5D dual-targeted CAR-T therapy; and Johnson & Johnson developed GPRC5D/CD3 dual antibody Talquetamab, the total response rate of the phase 1 study (ORR) up to 70%
.
GPRC5D (an orphan G protein-coupled receptor) exposed epitopes on the cell membrane transmits extracellular signals, which can promote the formation of tighter immune synapses between T cells and target cells, thereby increasing cytotoxicity
.
GPRC5D is a seven-pass transmembrane protein with a very complex structure, which brings great challenges to antibody preparation and activity analysis
.
Reference materials: 1.
https:// / /485/eaau7746/tab-figures-data4.
Kaifa Bio "Global First Release of GPRC5D Full-length Protein" 5.
Medical Notes "Multiple Myeloma Enters the Era of Macromolecules: CD38-BCMA-GPRC5D" Yimaike is always committed With original news reports on cutting-edge technologies, industry trends, and industry insights in bio-innovative drugs, the number of high-end matrix users in all media reached 160,000+, of which industrial users accounted for more than 50%, scientific research and clinical users accounted for about 30%, and investment institutional users exceeded 5%
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
